Formulation Development
IMUNON Announces Oral Presentation Highlighting Unprecedented Survival Data From Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
IMUNON recently announced new positive data from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer.…
WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges
Veterinary medicines face unique challenges due to species diversity, physiology, and dosing needs. Animals can’t be instructed to take medicine, so palatability, safety, and bioavailability are key.
Lonza Launches Design2Optimize Platform to Streamline API Development
Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today the launch of its new Design2Optimize platform to enhance process development…
Sanofi to Acquire Vigil Neuroscience, Adding a New Investigational Medicine to Treat Alzheimer’s Disease
Sanofi recently announced it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies…
Amphista Therapeutics Showcases Cryo-EM Enabled Platform for Discovering Novel Targeted Glue Degraders
Amphista Therapeutics presented its unique approach to constructing novel, orally bioavailable Targeted Glue protein degraders with mechanisms of action (MoA) distinct from traditional CRBN/VHL approaches…
Belite Bio Announces Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
Belite Bio, Inc. recently announced the US FDA has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease (STGD1) based on the…
Kaida BioPharma Announces New Partnership With Northway Biotech for the Manufacturing of KAD101
Kaida BioPharma recently announced it has entered into a manufacturing agreement with Northway Biotech, Inc. for the manufacturing of lead product candidate, KAD101. Under the…
Montara Therapeutics to Develop Novel Treatments Using the BrainOnly Platform
Montara Therapeutics recently announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in addition to joining MJFF’s…
Philikos Announces Initiation of Clinical Phase 1/2 Study With T-Guard in Patients With Systemic Sclerosis
Philikos B.V. recently announced it has enrolled the first patient in a Phase 1/2 clinical trial designed to evaluate the use of T-Guard for the…
CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing
CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for…
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing & Evidence of Early Immune Activation Signals
GT Biopharma, Inc. recently announced successful completion of dosing in Cohort 1 and subsequent initiation of dosing in Cohort 2 of its Phase 1 dose escalation…
Fujifilm Validates Cancer Cell-Targeting Potential of Peptide Oligonucleotide Conjugates With Novel Cyclic Peptides
FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with cyclic peptides developed…
SISCAPA & Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions
SISCAPA Assay Technologies and Biognosys recently announced an exclusive strategic collaboration to offer biopharma customers a streamlined end-to-end solution for high-sensitivity protein analysis—from early protein…
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of an Investigational Prime Editor for Chronic Granulomatous Disease
Prime Medicine, Inc. recently announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in Chronic Granulomatous…
Rani Therapeutics Announces Research Agreement With Chugai
Rani Therapeutics Holdings, Inc. recently announced it has entered into a Research Agreement on August 13, 2024, for two molecules with undisclosed targets provided by…
Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, recently announced the formation of its Scientific Advisory Board (SAB) composed of…
Cybin Engages Thermo Fisher Scientific to Provide US-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
Cybin Inc. recently announced it has engaged Thermo Fisher Scientific to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, the company’s…
Record-Breaking FDA Biosimilar Approvals to Create Opportunities for Drug Developers & Manufacturers
FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone trend. This presents a golden opportunity for…
Hovione & Firstgene Announce Strategic Collaboration to Advance Virus-Like Particle Platform for Liver Cancer
Hovione and Firstgene Life Sciences recently announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular…
Septerna & Novo Nordisk to Collaborate on Oral Small Molecule Medicines for Obesity & Other Cardiometabolic Diseases
Septerna, Inc. and Novo Nordisk recently announced an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small molecule medicines for obesity,…
